Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
Metric Value Shares sold (indirect) Transaction value $127.4 million Post-transaction shares (indirect) Transaction value based on SEC Form 4 reported price ($36.40). What is the significance of the 3,500,000-share sale in terms of Fairmount Funds Management LLC's overall position? This transaction reduced indirect holdings by 38.87%, leaving 5,503,418 shares. What was the market context for Cogent Biosciences shares at the time of the transaction? Shares were priced at around $36.40 during the reported sale (Jan. 22, 2026), lower than the closing price that day of $39.53. Metric Value *Price Market capitalization $5.46 billion Net income (TTM) -$294.37 million *1-year price change * Price 1-year price change calculated using Jan. 31, 2026 as the reference date. Based in Massachusetts, Cogent Biosciences is a clinical-stage biotechnology company specializing in targeted therapies for rare, genetically driven diseases. The company's strategy lev
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences (NASDAQ:COGT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=COGT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Cogent Biosciences announcse U.S. BTD for bezuclastinib [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)GlobeNewswire
COGT
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/22/26 - Form 4
- 1/22/26 - Form 144
- COGT's page on the SEC website